Biosimilar approval and adoption in the U.S. needs to be expedited - STAT

Biosimilar approval and adoption in the U.S. needs to be expedited - STAT

Biosimilar approval and adoption in the U.S. needs to be expedited

By CARLOS SATTLER AND SHEILA FRAME

APSTOCK

Wider use of biosimilars will save the U.S. billions on pricey biologic drugs — if we can break down the barriers to their adoption.

READ MORE